If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.125    -0.125 (-1.52%)
Bid:
8.00
Ask:
8.25
Spread: 0.25 (3.125%)
Market Cap: £17.79m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

6 Feb 2012 09:25

RNS Number : 8480W
Phytopharm PLC
06 February 2012
Β 

Phytopharm plc

Β 

Annual Information Update

Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 6 February 2012, the following information has been published or made available to the public between 8 February 2011 and 6 February 2012 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.

1. Announcements made via the Regulatory Information Service ("RIS")

All the announcements listed below were published through a regulatory information service on the dates indicated. Copies can be obtained from the London Stock Exchange website, http://www.londonstockexchange.com or from the Company's website www.phytopharm.com

Date of publication

Title

2 February 2012

Appointment of Non-Executive Director

27 January 2012

Publication of 2011 annual report

16 January 2012

Research update

11 January 2012

Block listing cancellation

3 January 2012

Block listing interim review

28 November 2011

Director/PDMR shareholding

28 November 2011

Director/PDMR shareholding

24 November 2011

Final results

8 November 2011

Notice of results

7 November 2011

Block listing interim review

4 October 2011

Research update

29 September 2011

Research update

16 August 2011

Interim management statement

28 July 2011

Research update

12 July 2011

Block listing interim review

5 July 2011

Total voting rights

17 June 2011

Block listing interim review

26 May 2011

Half yearly report

17 May 2011

Notice of results

5 May 2011

Block listing interim review

31 March 2011

Results of AGM

2 March 2011

Holding(s) in Company

15 February 2011

Interim management statement

7 February 2011

Annual information update

2. Documents published or sent to Shareholders or submitted to the FSA including those filed with the National Storage Mechanism:

Date of publication

Title

27 January 2012

Annual Report 2011

26 May 2011

Interim Report 2011

30 March 2011

AGM resolutions 2011

The 2011 Interim and 2011 Annual reports are available on the Company's website www.phytopharm.com

3. Documents filed at Companies House

The following documents were files at Companies House. Copies of these documents can be obtained from the Companies House website at www.companieshouse.gov.uk, or Companies House, Crown Way, Cardiff CF14 3UZ

Date of Publication

Title

2 January 2012

Form AP01 Appointment of Director

27 January 2012

Annual Report 2011

15 December 2011

Form AR01 Annual return

5 December 2011

Form AD02 Single alternative inspection location

6 June 2011

Form AH01 Return of allotment of shares on 6 June 2011

31 March 2011

AGM resolutions

Copies of all documents referred to above are also available for inspection at the Company's registered office (Lakeview House, 2 Lakeview Court, Ermine Business Park, Huntingdon, Cambridgeshire PE29 6UA, United Kingdom) during normal business hours or by written request from the Company Secretary.

This annual information is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented by the UK Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express of implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, not referred to in it, constitutes, by virtue of this communication, an offer of securities addressed to any person and it should not be relied on by any person.

For further information, please contact:

Zoe McGowan, Company Secretary

Phytopharm plc Tel No: +44 (0)1480 437697

Further information about Phytopharm can be found on the Company's website www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
AIUEANAKEAAAEEF
Date   Source Headline
3rd May 20187:00 amRNSNotice of Interim Results
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options
30th Jan 201710:28 amRNSResult of AGM
17th Jan 20174:09 pmRNSDirector/PDMR Shareholding
17th Jan 20177:00 amRNSAppointment of Giulio Cerroni as CEO
16th Jan 20172:00 pmRNSAnnual Report and Accounts and Notice of AGM
13th Jan 20173:25 pmRNSHolding(s) in Company
12th Jan 20172:56 pmRNSHolding(s) in Company
4th Jan 20173:43 pmRNSIssue of 590,093 Deferred Consideration Shares
23rd Dec 20167:00 amRNSBuyback and Cancellation of Deferred Shares
20th Dec 20167:00 amRNSFull Year Results
16th Nov 20167:00 amRNSParticipation in major EU partnership (ROADMAP)
21st Oct 20167:00 amRNSPre-Close Trading Update
20th Oct 20167:00 amRNS$1.2m contract with new global pharma customer
19th Oct 20167:00 amRNSIXICO presents at CAMD regulatory workshop
10th Oct 20167:00 amRNSEUR1m funding as a partner in major EU consortium
3rd Oct 20167:00 amRNSAppointment of Shore Capital as Nominated Adviser
3rd Oct 20167:00 amRNSAppointment of Shore Capital
26th Sep 20165:14 pmRNSDirector/PDMR Shareholding
26th Sep 20161:58 pmRNSExercise of Share Options
16th Sep 20167:00 amRNSBoard changes
13th Sep 20167:00 amRNSPresentation of Assessa® PML at ECTRIMS
29th Jul 201610:25 amRNSWeb-Based Technology Improves Paediatric ADHD Care
7th Jun 20167:00 amRNSHalf Yearly Report to 31 March 2016
2nd Jun 20167:00 amRNSCygnus joins Dementias Platform UK

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.